Published in J Clin Oncol on October 30, 2006
Management of oral mucositis in patients who have cancer. Dent Clin North Am (2008) 1.72
Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer. J Clin Oncol (2007) 1.39
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.26
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.17
Normal tissue protection for improving radiotherapy: Where are the Gaps? Transl Cancer Res (2012) 1.03
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid (2010) 1.01
Radiation induced oral mucositis. Indian J Palliat Care (2009) 0.93
Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics (2009) 0.91
Whose opinion counts? J Clin Oncol (2006) 0.87
Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer. J Thorac Oncol (2012) 0.85
Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med (2013) 0.81
Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life. Support Care Cancer (2009) 0.80
The Expression of Inflammatory Mediators in Bladder Pain Syndrome. Eur Urol (2016) 0.79
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer (2011) 0.78
Preventive effects of amino-acid-rich elemental diet Elental(®) on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study. Support Care Cancer (2015) 0.78
The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer (2008) 0.77
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.76
Supportive treatments for oncology patients: not just icing on the cake. Ann Intern Med (2010) 0.75
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol (2007) 6.82
Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med (2004) 6.26
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol (2012) 4.91
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Temperature-sensitive control of protein activity by conditionally splicing inteins. Nat Biotechnol (2004) 2.62
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology (2014) 2.09
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol (2003) 1.80
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) (2008) 1.78
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res (2010) 1.73
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol (2006) 1.68
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
A novel diagnostic test detects a low frequency of the hemicentin Gln5345Arg variant among Northern Irish age related macular degeneration patients. Mol Vis (2004) 1.64
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer (2010) 1.55
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res (2005) 1.52
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Cardiac surgeon report cards, referral for cardiac surgery, and the ethical responsibilities of cardiologists. J Am Coll Cardiol (2012) 1.51
Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol (2011) 1.51
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol (2004) 1.48
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol (2011) 1.47
Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov (2011) 1.45
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology (2009) 1.43
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU Int (2013) 1.39
Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One (2010) 1.36
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol (2006) 1.35
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist (2012) 1.34
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
The case for strategic international alliances to harness nutritional genomics for public and personal health. Br J Nutr (2005) 1.24
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer (2012) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. Psychooncology (2005) 1.19
Pigmented paravenous chorioretinal atrophy is associated with a mutation within the crumbs homolog 1 (CRB1) gene. Invest Ophthalmol Vis Sci (2005) 1.18
Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res (2012) 1.17
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol (2013) 1.16
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14
p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum (2003) 1.14
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol (2012) 1.10
The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 1.08
Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts. Cytometry B Clin Cytom (2012) 1.08
Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS One (2010) 1.08
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun (2003) 1.08
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer (2010) 1.05
The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia Pac J Clin Oncol (2010) 1.05
Positron emission tomography and molecular imaging of the prostate: an update. BJU Int (2006) 1.03
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol (2006) 1.03
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol (2009) 1.03
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood (2003) 1.03
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol (2009) 1.01
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res (2007) 1.01
Medical Qigong for cancer patients: pilot study of impact on quality of life, side effects of treatment and inflammation. Am J Chin Med (2008) 1.00
Medical paternalism and expensive unsubsidised drugs. BMJ (2005) 1.00
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res (2005) 1.00
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol (2012) 0.99
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res (2013) 0.98
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
Body image as a predictor of psychopathology in surgical patients with colorectal disease. J Psychosom Res (2012) 0.97
Influence of gestational age and fetal iron status on IRP activity and iron transporter protein expression in third-trimester human placenta. Am J Physiol Regul Integr Comp Physiol (2004) 0.96
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer (2011) 0.96
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One (2012) 0.96
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res (2012) 0.96
A critical review of the effects of medical Qigong on quality of life, immune function, and survival in cancer patients. Integr Cancer Ther (2011) 0.96
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer (2012) 0.95
CD22 as a target of passive immunotherapy. Semin Oncol (2003) 0.95
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res (2009) 0.94
Assessment of futility in clinical trials. Pharm Stat (2007) 0.94